CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $215.34M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -2.65: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
215.34MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9360xvs all stocks
52-Week Change
4.33%vs all stocks
Market Capitalization
215.34MUSDvs all stocks (USD)
Enterprise Value
127.05MUSDvs all stocks (USD)
Forward P/E
-3.44xvs Biotechnology peers
Price to Book (MRQ)
2.98xvs Biotechnology peers
Enterprise to EBITDA
-1.09xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-39.02%vs Biotechnology peers
Return on Equity (TTM)
-110.71%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-98.56MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-73.86MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-83.25MUSDvs all stocks (USD)
Pre-tax Income
-45.58MUSDFY2025 · Dec 31, 2025Income Tax Expense
35.00KUSDFY2025 · Dec 31, 2025Net Income
-45.62MUSDFY2025 · Dec 31, 2025EBIT
-83.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-116.39MUSDFY2025 · Dec 31, 2025Research & Development
66.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.98MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5200USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-45.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-28.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-45.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
313.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.45MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-313.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-161.13MUSDFY2025 · Dec 31, 2025Sale of Investments
171.93MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
10.79MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
53.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
80.89MSharesUpdated Sep 27, 2026Float Shares
74.60MSharesUpdated Sep 27, 2026Shares Short
8.26MSharesUpdated Sep 27, 2026Short Ratio
8.70daysvs all stocks
Short % of Shares Outstanding
10.17%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
62.53%vs all stocks
Total Cash (MRQ)
88.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.09USDUpdated Sep 27, 2026Total Debt (MRQ)
467.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0065xvs Biotechnology peers
Current Ratio (MRQ)
7.90xvs Biotechnology peers
Book Value per Share (MRQ)
0.8900USDUpdated Sep 27, 2026Total Assets
169.01MUSDvs all stocks (USD)
Total Current Assets
135.69MUSDFY2025 · Dec 31, 2025Total Liabilities
87.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
18.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
110.53MUSDFY2025 · Dec 31, 2025Accounts Payable
3.63MUSDFY2025 · Dec 31, 2025Short-term Debt
358.00KUSDFY2025 · Dec 31, 2025Long-term Debt
283.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
75.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-401.20MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
81.08MUSDvs all stocks (USD)
52-Week Low
1.35USDUpdated Sep 27, 202652-Week High
4.60USDUpdated Sep 27, 202652-Week Change
4.33%vs all stocks
Beta
0.9360xvs all stocks
50-Day MA
3.30USDUpdated Sep 27, 2026200-Day MA
3.01USDUpdated Sep 27, 2026Avg 10-Day Volume
910.74KSharesUpdated Sep 27, 2026Avg 30-Day Volume
968.18KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9000USDUpdated Sep 27, 2026Other Income / Expense
37.67MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 7.90Altman Z-Score: -2.65
Financial Health
Altman Z-Score -2.65: distress zoneCritical
Altman Z-Score: -2.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $215.34M, lower than 95% of all stocks globallySignificant
Market cap (USD): 215,342,052Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Xianheng International Science And Technology Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline